Predictive factors for relapse in patients on buprenorphine maintenance

American Journal on Addictions

Volumn 23, Issue 1, 2014, Pages 62-67

  Ferri, Michael ^a   Finlayson, Alistair J Reid ^a   Wang, Li ^a   Martin, Peter R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; BUPRENORPHINE PLUS NALOXONE; CONTROLLED SUBSTANCE; DIAMORPHINE; BUPRENORPHINE; NARCOTIC ANTAGONIST;

ADULT; ALCOHOL ABUSE; ANXIETY DISORDER; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DRUG CONTROL; DRUG USE; DYSTHYMIA; EMPLOYMENT STATUS; FEMALE; HEALTH INSURANCE; HEROIN DEPENDENCE; HUMAN; INTRAVENOUS DRUG ABUSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MARRIAGE; MEDICAL RECORD REVIEW; OPIATE ADDICTION; PANIC; POSTTRAUMATIC STRESS DISORDER; PRESCRIPTION; RELAPSE; RESIDENTIAL CARE; RISK FACTOR; SELF REPORT; TOXICOLOGY; TREATMENT OUTCOME; MAINTENANCE CHEMOTHERAPY; OPIOID-RELATED DISORDERS; RECURRENT DISEASE; RETROSPECTIVE STUDY; YOUNG ADULT;

ADULT; BUPRENORPHINE; FEMALE; HUMANS; MAINTENANCE CHEMOTHERAPY; MALE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84890032979     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/j.1521-0391.2013.12074.x     Document Type: Article

References (14)

1. Substance Abuse and Mental Health Services Administration. Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-41, HHS Publication No. (SMA) 11-4658. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2011.
2. CDC. CDC grand rounds: Prescription drug overdoses-A U.S. epidemic. MMWR Morb Mortal Wkly Rep. 2012; 61: 10-13.
3. Feillin D, O'Connor P., Office-based treatment of opioid-dependent patients. N Engl J Med. 2002; 347: 817-823.
4. Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003; 349: 949-958.
5. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE., A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med. 2000; 343: 1290-1297.
6. Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial. Arch Gen Psychiat. 2011; 68: 1238-1246.
7. Subramaniam GA, Warden D, Minhajuddin A, et al. Predictors of abstinence: National Institute of Drug Abuse multisite buprenorphine/naloxone treatment trial in opioid-dependent youth. J Am Acad Child Adolesc Psychiatry. 2011; 50: 1120-1128.
8. Fareed A, Vayalapalli S, Casarella J, Drexler K., Effect of buprenorphine dose on treatment outcome. J Addict Dis. 2012; 31: 8-18.
9. Equianalgesic Chart. www2.massgeneral.org/painrelief/Equianalgesia.pdf. Accessed June 2010.
10. Benningfield MM, Dietrich MS, Jones HE, et al. Opioid dependence during pregnancy: Relationships of anxiety and depression symptoms to treatment outcomes. Addiction. 2012; 107 (Suppl 1): 74-82.
11. Gerra G, Borella F, Zaimovic A, et al. Buprenorphine versus methadone for opioid dependence: Predictor variables for treatment outcome. Drug Alcohol Depend. 2004; 75: 37-45.
12. Hillhouse M, Canamar CP, Doraimani G, et al. Participant characteristics and buprenorphine dose. Am J Drug Alcohol Abuse. 2011; 37: 453-459.
13. Martin PR, Patel S, Swift RM., Pharmacology of drugs of abuse. In:, Golan D, Tashjian AH, Armstrong EJ, Armstrong A, eds. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy, 3rd edn, pp. 284-309. Philadelphia: Lippincott Williams & Wilkins; 2012.
14. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: A randomized controlled trial. JAMA. 2006; 295: 2003-2017.